Carrier testing strategy in haemophilia a using two polymorphic DNA probes of the factor VIIi gene
Intrator, S.; Noel, B.; Lucotte, G.
Experimental Hematology 15(3): 304-305
1987
ISSN/ISBN: 0301-472X PMID: 3102274 Document Number: 304183
Document emailed within 1 workday
Related Documents
Dormandy, K.M.; Sultan, Y. 1975: The suppression of factor VIIi antibodies in haemophilia Pathologie-Biologie 23 Suppl: 17-23Mahasandana, C.; Suvatte, V.; Püng-amritt, P.; Tuchinda, S. 1979: Von Willebrand's disease: studies of platelet functions, factor VIII procoagulant activity (F VIII C) and factor VIII-related antigen (F VIII RAg) in three families Southeast Asian Journal of Tropical Medicine and Public Health 10(2): 243-247
Brown, J.E.; Carton, C.L.; Hougie, C. 1981: The effect of naturally occurring antibodies to factor VIIi on an immunoradiometric assay for factor VIIi coagulant antigen. Observation on a cross-reacting material-positive (CRM+) hemophiliac with a factor VIIi inhibit Journal of Laboratory and Clinical Medicine 97(1): 65-71
Aznar, J.A.; Jorquera, J.I.; Peiró, A.; Garcia, I. 1984: The importance of corticoids added to continued treatment with Factor VIIi concentrates in the suppression of inhibitors in haemophilia a Thrombosis and Haemostasis 51(2): 217-221
Kochhan, L.; Lalloz, M.R.; Oldenburg, J.; McVey, J.H.; Olek, K.; Brackmann, H.H.; Tuddenham, E.G.; Schwaab, R. 1994: Haemophilia A diagnosis by automated fluorescent DNA detection of ten factor VIII intron 13 dinucleotide repeat alleles Blood Coagulation and Fibrinolysis: An International Journal in Haemostasis and Thrombosis 5(4): 497-501
Hay, C.R.; Colvin, B.T.; Ludlam, C.A.; Hill, F.G.; Preston, F.E. 1996: Recommendations for the treatment of factor VIII inhibitors: from the UK Haemophilia Centre Directors' Organisation Inhibitor Working Party Blood Coagulation and Fibrinolysis: An International Journal in Haemostasis and Thrombosis 7(2): 134-138
Ockelford, P.A.; Lowe, G.; Johns, A.S.; Berry, E.W. 1986: Comparison of methods of plasma volume determination for dose calculation of factor VIII in patients with classic haemophilia New Zealand Medical Journal 99(796): 116-119
Takahashi, I.; Furuta, M.; Mizuno, S.; Takamatsu, J.; Kamiya, T. 1993: Effect of substrate and diluent for factor VIIi activity in highly purified factor VIIi concentrate and patient plasma infused factor VIIi concentrate Rinsho Byori. Japanese Journal of Clinical Pathology 41(7): 825-830
Hay, C.R.; Lozier, J.N.; Lee, C.A.; Laffan, M.; Tradati, F.; Santagostino, E.; Ciavarella, N.; Schiavoni, M.; Fukui, H.; Yoshioka, A.; Teitel, J.; Mannucci, P.M.; Kasper, C.K. 1996: Safety profile of porcine factor VIII and its use as hospital and home-therapy for patients with haemophilia-A and inhibitors: the results of an international survey Thrombosis and Haemostasis 75(1): 25-29
Muntean, W. 1984: Purified complex of factor VIII coagulant moiety and phospholipid: high factor VIII coagulant activity in factor VIII inhibitor plasma Wiener Klinische Wochenschrift 96(22): 829-832
Tran, T.H.; Duckert, F. 1983: Dissociation of factor VIIi procoagulant antigen VIII:CAg and factor VIIi related antigen VIIIR:Ag by EDTA - influence of divalent cation on the binding of VIII:CAg and VIIIR:Ag Thrombosis and Haemostasis 50(2): 547-551
Sacchi, E.; Stefanile, C.; Tagliavacca, L.; Mannucci, P.M.; Bianchi Bonomi, A. 1992: Usefulness of determination of factor VIIi intron 7 polymorphism by a non-radioactive technique for carrier detection of hemophilia a Thrombosis and Haemostasis 68(5): 622-623
Tinlin, S.; Webster, S.; Giles, A.R. 1993: The development of homologous (canine/anti-canine) antibodies in dogs with haemophilia A (factor VIII deficiency): a ten-year longitudinal study Thrombosis and Haemostasis 69(1): 21-24
Jayandharan, G.R.; Shaji, R.V.; Baidya, S.; Nair, S.C.; Chandy, M.; Srivastava, A. 2005: Molecular characterization of factor IX gene mutations in 53 patients with haemophilia B in India Thrombosis and Haemostasis 94(4): 883-886
Scheibel, E.; Ingerslev, J.; Dalsgaard-Nielsen, J.; Stenbjerg, S.; Knudsen, J.B. 1987: Continuous high-dose factor VIII for the induction of immune tolerance in haemophilia A patients with high responder state: a description of eleven patients treated Thrombosis and Haemostasis 58(4): 1049-1052
Teitel, J.M.; Lau, H.K.; Garvey, M.B. 2002: Discrepancies in measured factor VIIi activity in patients treated with factor VIIi concentrate of human or porcine origin Thrombosis and Haemostasis 88(1): 159-160
Brettler, D.B.; Forsberg, A.D.; Levine, P.H.; Aledort, L.M.; Hilgartner, M.W.; Kasper, C.K.; Lusher, J.M.; McMillan, C.; Roberts, H. 1989: The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience Archives of Internal Medicine 149(6): 1381-1385
Liebe, S. 1982: Activation of the antihemophilic globulin a (factor VIII). 2. Effect of ampholine on the course of blood coagulation and the molecular conformation of factor VIIi Zeitschrift für die Gesamte Innere Medizin und ihre Grenzgebiete 37(4): 110-116
Allersma, D.P.; Smid, W.M.; van der Does, J.A.; van der Meer, J.; Briët, E. 1996: Effects of chronic factor VIII substitution on immune parameters in HIV seronegative haemophiliacs: a comparison between cryoprecipitate and factor VIII concentrate Thrombosis and Haemostasis 75(2): 261-266
Poon, M.C.; Hoar, D.I.; Low, S.; Pon, J.K.; Anand, S.; Sinclair, G.D. 1992: Hemophilia a carrier detection by restriction fragment length polymorphism analysis and discriminant analysis based on ELISA of factor VIIi and vWf Journal of Laboratory and Clinical Medicine 119(6): 751-762